5 recruiting, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SHR-A1921: new trials by email Literature Review of SHR-A1921 trials Research Report on SHR-A1921
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer SHR-A1921, Adebrelimab - Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2024-12-01 | 2024-12-20 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer SHR-A1811, SHR-A1921, Adebrelimab - Advanced Breast Cancer | Phase 2 | Recruiting | Beijing GoBroad Hospital | 113 | 2024-08-05 | 2026-07-14 |
| Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC SHR-A2009, SHR-A1921 - NSCLC | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 30 | 2024-06-01 | 2024-06-20 |
| SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer SHR-A1921, Doxorubicin, Paclitaxel - Ovarian Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 440 | 2024-05-10 | 2024-08-09 |
| A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing SHR-A1811, SHR 3680 + leuprolide, SHR-A1921 - Advanced Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Fudan University | 88 | 2023-07-26 | 2026-04-02 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours SHR-A1921 - Advanced Solid Tumours | Phase 1 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 156 | 2021-12-31 | 2021-12-13 |
Breast Neoplasms (3) · Triple Negative Breast Neoplasms (2) · Ovarian Neoplasms (1)
Fudan University (5) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Beijing GoBroad Hospital (1) · Henan Cancer Hospital (1)
China (8)
Dongmei Ji, Doctor (1) · Hongxia Wang (1) · Wei Zhao (1) · Zhimin Shao, M.D. (1) · Zhimin Shao, Professor (1)